Market Overview

UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 PT Post Analyst Day

Related CPHD
Analysts Give Healthcare Sector A Clean Bill Of Health
Cepheid Margin Expansion Unlikely To Morgan Stanley, Stays On Sidelines

Canaccord Genuity maintained its Buy rating and $50 price target on Cepheid (NASDAQ: CPHD).

Canaccord Genuity noted, "We reiterate our BUY rating and $50 price target on CPHD given its solid 20% revenue growth, large customer base (approaching 3,000), and an unmatched test menu (11 FDA approved assays). Cepheid's analyst day provided an update to investors on its long-term financial targets, competitive advantages, and future products. However, due to three consecutive missed quarters, no EPS visibility, and lengthening selling cycles, CPHD shares experienced a pullback."

Cepheid closed at $35.18 on Thursday.

Latest Ratings for CPHD

Aug 2016JefferiesMaintainsHold
Jul 2016JP MorganMaintainsNeutral
Jun 2016Morgan StanleyInitiates Coverage onEqual-weight

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (CPHD)

View Comments and Join the Discussion!